新产品编号:2351361

Chemical Name: 5-Bromo-2-[N-[4-(2-butynyloxy)phenylsulfonyl]-N-methylamino]-3-(4-methylpiperazin-1-ylmethyl)benzohydroxamic acid
项目整合开发状态: Preclinical
项目研究机构: Amgen (Originator), Wyeth Pharmaceuticals (Originator)
合成路线:Sulfonylation of methyl 5-bromo-3-methylanthranilate (I) with acid chloride (II) affords sulfonamide (III).Subsequent alkylation of the sulfonamide N of (III) with iodomethane and K2CO3 yields (IV).After protection of the phenolic hydroxyl group of (IV) as the silyl ether (V),benzylic halogenation with N-bromosuccinimide furnishes bromide (VI).Displacement of its benzylic bromide with 1-methylpiperazine (VII) occurs with concomitant desilylation to give (VIII).Mitsunobu coupling of phenol (VIII) with 2-butyn-1-ol (IX) leads to the propargyl ether (X).The methyl ester group of (X) is then hydrolyzed under alkaline conditions to furnish the carboxylic acid (XI).

合成路线:Acid (XI) is then activated as the corresponding acid chloride (XII) upon treatment with oxalyl chloride in the presence of DMF.Finally,reaction of acid chloride (XII) with hydroxylamine leads to the title hydroxamic acid.